Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:26 PM ET 8-K/A
Divestiture Clarivate PLC CLVT

Clarivate Divestiture to Altaris, LLC for $600M

Clarivate Plc completed the sale of its Life Sciences and Healthcare (LS&H) business to an affiliate of Altaris, LLC for an aggregate purchase price of $600 million. The consideration consists of $500 million in cash, a $75 million unsecured senior note, and $25 million in deferred cash consideration. The transaction represents a strategic shift for Clarivate and will be classified as discontinued operations.

Value
$600M
Counterparty
Altaris, LLC
4:17 PM ET 8-K
M&A Deal Black Hawk Acquisition Corp BKHA

Black Hawk Acquisition M&A Deal with Vesicor Therapeutics, Inc.

Black Hawk Acquisition Corporation shareholders approved its business combination with Vesicor Therapeutics, Inc. at an extraordinary general meeting. The approval includes the domestication of the company from the Cayman Islands to Delaware and the election of five directors to the post-combination board. This represents a status update on a pending merger as the SPAC moves toward closing the transaction.

Counterparty
Vesicor Therapeutics, Inc.
4:16 PM ET 8-K
Divestiture McEwen Inc. MUX

McEwen Divestiture to Dome Mine Ltd. for $55M

McEwen Inc. entered into a definitive agreement to sell its Fuller and Paymaster properties in Timmins, Ontario to Dome Mine Ltd. for $55 million. The consideration consists of $5 million in cash and $50 million in Discovery Mining Ltd. common shares. The company also received $13.5 million in cash by assigning a pre-existing loan receivable to third-party lenders to enhance liquidity.

Value
$55M
Counterparty
Dome Mine Ltd.
4:10 PM ET 8-K
M&A Deal Atii Holdings Inc. NANO

Atii Holdings Signs $100M M&A Deal with Forge Nano, Inc.

Archimedes Tech SPAC Partners II Co. (ATII) provided an update on its pending business combination with Forge Nano, Inc. The parties entered into an amended subscription agreement for a $100 million PIPE investment, modifying the structure so that a portion of the investment will be issued as pre-funded warrants instead of common stock.

Value
$100M
Counterparty
Forge Nano, Inc.
4:07 PM ET 8-K
M&A Deal Weave Communications, Inc. WEAV

Weave Communications M&A Deal with Willow Parent, LLC

Weave Communications provided a status update on its pending acquisition by Willow Parent, LLC (an affiliate of Francisco Partners), specifically addressing stockholder litigation and demand letters. The company is issuing supplemental proxy disclosures to resolve allegations of incomplete information in its definitive proxy statement and avoid potential delays to the merger. A special meeting for stockholders to vote on the merger is scheduled for October 22, 2026.

Counterparty
Willow Parent, LLC
4:06 PM ET 8-K
M&A Deal Quantumsphere Acquisition Corp QUMS

Quantumsphere Acquisition Signs $600M M&A Deal with Fortune Favor Technology Inc.

Quantumsphere Acquisition Corporation (QUMS) entered into a definitive merger agreement with Fortune Favor Technology Inc., a medical cold-chain technology consulting firm. The transaction implies a pre-money equity valuation of $600 million for Fortune Favor, which will become a wholly owned subsidiary of a new publicly traded entity. Upon closing, Fortune Favor's management team is expected to lead the combined company.

Value
$600M
Counterparty
Fortune Favor Technology Inc.
4:06 PM ET 8-K
Divestiture B&G Foods, Inc. BGS

B&G Foods Divestiture to McCall Farms, Inc.

B&G Foods has sold its B&M and Joan of Arc canned bean brands to McCall Farms, Inc. as part of a strategic effort to simplify its portfolio and reduce leverage. The company intends to use the net proceeds from the sale to repay long-term debt.

Counterparty
McCall Farms, Inc.
4:04 PM ET 8-K
Capital Raise Grayscale Bittensor Trust (TAO) GTAO

Grayscale Bittensor Trust Capital Raise of $1.45M

Grayscale Bittensor Trust (TAO) issued 253,100 shares to accredited investors in private placement transactions exempt from registration under Rule 506(c). The trust received an aggregate of 4,777.99171760 TAO tokens, valued at approximately $1.45 million, in exchange for the shares. As of October 13, 2026, the trust has 3,247,300 shares issued and outstanding.

Value
$1.45M
Counterparty
accredited investors
4:01 PM ET 8-K/A
M&A Deal Tarsus Pharmaceuticals, Inc. TARS

Tarsus Pharmaceuticals M&A Deal with Alkeus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals filed an amendment to its previous 8-K to provide required historical and pro forma financial statements following its acquisition of Alkeus Pharmaceuticals. The acquisition was originally completed on September 4, 2026, pursuant to a merger agreement dated July 31, 2026.

Counterparty
Alkeus Pharmaceuticals, Inc.
12:20 PM ET 8-K
Capital Raise Bridgecrest Lending Auto Securitization Trust 2026-4

Bridgecrest Lending Auto Securitization Trust 2026-4 Capital Raise

Bridgecrest Lending Auto Securitization Trust 2026-4 is filing legal and tax opinions in connection with the issuance of several classes of Auto Loan Asset Backed Notes (Class A-1 through Class D). This filing satisfies regulatory undertakings related to a takedown from an existing registration statement for the public offering of these asset-backed securities.

9:42 AM ET 8-K
M&A Deal Cavitation Technologies, Inc. CVAT

Cavitation Technologies Signs $42M M&A Deal with BrightFlixx Finance S.A.

Cavitation Technologies, Inc. (CVAT) and its 17%-owned affiliate Alchemy Beverages Inc. have entered into definitive agreements with BrightFlixx Finance for all-cash tender offers to acquire both companies. The aggregate deal value is $42 million, with $35 million allocated to CVAT and $7 million to Alchemy, replacing previous agreements with European Guarantee Services.

Value
$42M
Counterparty
BrightFlixx Finance (Luxembourg) S.A.
9:29 AM ET 8-K
M&A Deal Alaunos Therapeutics, Inc. TCRT

Alaunos Therapeutics M&A Deal with Velaris Therapeutics, Inc.

Alaunos Therapeutics completed the acquisition of Velaris Therapeutics through a two-step merger process, making Velaris a wholly owned subsidiary. As consideration, Alaunos issued 105,286 shares of Series B Preferred Stock and 33,054 shares of Series C Preferred Stock to Velaris stockholders, which are convertible into common stock subject to shareholder approval. Following the deal, Alaunos plans to change its name to Velaris Therapeutics, Inc. and effect a reverse stock split.

Counterparty
Velaris Therapeutics, Inc.
9:26 AM ET 8-K
M&A Deal Ssr Mining Inc. SSRM

Ssr Mining Signs $464M M&A Deal with Roxmore Resources Inc.

SSR Mining has entered into a definitive agreement to acquire all outstanding shares of Roxmore Resources for C$6.75 per share in cash, representing a total equity value of approximately $464 million. The deal includes Roxmore's Converse Gold Project in Nevada, which SSR Mining plans to develop as a contiguous asset to its Marigold Complex to capture over $200 million in synergies. As part of the transaction, Roxmore will spin off its non-core exploration assets into a new company, SpinCo, in which SSR Mining will retain a 14.99% interest.

Value
$464M
Counterparty
Roxmore Resources Inc.
9:23 AM ET 8-K
Clinical Trial Data bioAffinity Technologies, Inc. BIAF

bioAffinity Technologies Clinical Trial Data

bioAffinity Technologies announced it will present positive research data at the CHEST 2026 annual meeting regarding its sputum-based tests for lung inflammation. The data demonstrates the ability to detect multiple protein biomarkers and biologic drug targets for asthma and COPD using the company's flow cytometry and AI platform. The research aims to support a precision medicine approach for identifying patients who could benefit from specific biologic therapies.

Counterparty
American College of Chest Physicians
9:07 AM ET 8-K
M&A Deal Cohen & Steers Income Opportunities REIT, Inc. CNSREIT

Cohen & Steers Income Opportunities REIT M&A Deal with Manchester Village

Cohen & Steers Income Opportunities REIT, Inc. (CNSREIT) has acquired Manchester Village, a 99%-occupied community shopping center in Rock Hill, South Carolina. The acquisition was made through a programmatic joint venture with the Sterling Organization and aligns with the REIT's strategy of investing in necessity-based retail in high-growth submarkets of the Charlotte metropolitan area.

Counterparty
Manchester Village
9:01 AM ET 8-K
M&A Deal Sizzle Acquisition Corp. II SZZL

Sizzle Acquisition Corp. II M&A Deal with Trasteel Holding S.A.

Sizzle Acquisition Corp. II provided a status update on its pending business combination with Trasteel Holding S.A. by furnishing Trasteel's first half 2026 financial results. Trasteel reported H1 2026 revenues of $1.19 billion and EBITDA of $50.7 million, while reaffirming its full-year 2026 revenue guidance of $2.1-$2.5 billion.

Counterparty
Trasteel Holding S.A.
8:57 AM ET 8-K
M&A Deal Bumble Inc. BMBL

Bumble Signs $1.3B M&A Deal with Ithaca Holdings

Bumble Inc. has entered into a definitive agreement to be acquired by Ithaca Holdings in an all-cash transaction valuing the company at $1.3 billion. Under the terms of the deal, Class A shareholders will receive $6.05 per share, representing a 138% premium to the unaffected closing price. Upon completion, Bumble will become a privately-held company and Ithaca Co-CEOs Ravi Gupta and John Hegeman will lead the company alongside founder Whitney Wolfe Herd.

Value
$1.3B
Counterparty
Ithaca Holdings
8:52 AM ET
Earnings Call Ondas Inc. ONDS ▶ Call

Ondas Earnings Call: Key Takeaways

Ondas is scaling rapidly through an integrated 'One Ondas' platform, raising 2026 revenue guidance significantly while leveraging a massive $757 million backlog and $11 billion pipeline.

8:47 AM ET 8-K
M&A Deal Workday, Inc. WDAY

Workday M&A Deal with ConductorOne, Inc.

Workday has entered into a definitive agreement to acquire C1.ai, a leading agentic identity platform for people and AI agents. The acquisition aims to integrate identity governance directly into Workday's core platform to manage real-time access for humans and autonomous agents across enterprise systems. The transaction is subject to customary closing conditions.

Counterparty
ConductorOne, Inc. (C1.ai)
8:39 AM ET 8-K
Partnership Ondas Inc. ONDS

Ondas Partnership with Palantir

Ondas Inc. and Palantir have launched Regna AI, a new standalone company and strategic partnership focused on providing sovereign AI solutions for defense and government sectors. Regna AI will utilize Palantir's AIP platform and Ondas' expertise in autonomous systems to deploy fine-tuned open-weight models that allow governments to maintain control over their mission data and AI models.

Counterparty
Palantir
8:36 AM ET 8-K
Clinical Trial Data CervoMed Inc. CRVO

CervoMed Clinical Trial Data

CervoMed announced positive initial 12-week biomarker data from its Phase 2a clinical trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA). The data showed a mean reduction in plasma neurofilament light chain (NfL) levels, a key marker of neurodegeneration, which contrasts with the increases typically seen in the natural history of the disease.

8:36 AM ET 8-K
Regulatory Approval SAB Biotherapeutics, Inc. SABS

SAB Biotherapeutics Regulatory Approval

SAB Biotherapeutics announced that the FDA has granted Fast Track designation to SAB-142, a fully human anti-thymocyte immunoglobulin being developed for Stage 3 type 1 diabetes. The designation is intended to expedite the development and review of the immunotherapy, which is currently in a Phase 2b clinical trial. Topline data from the SAFEGUARD study is anticipated in the second half of 2027.

8:33 AM ET 8-K
Clinical Trial Data First Tracks Biotherapeutics, Inc. TRAX

First Tracks Biotherapeutics Clinical Trial Data

First Tracks Biotherapeutics announced positive topline data from the first Phase 1b cohort of its drug candidate ANB033 for the treatment of Celiac Disease. The company also updated its corporate investor presentation to reflect these clinical developments.

8:30 AM ET 8-K
M&A Deal Horizon Space Acquisition I Corp. HSPOF

Horizon Space Acquisition I Signs $2B M&A Deal with ArcheNova Biotech Corp.

Horizon Space Acquisition I Corp. (HSPO), a SPAC, has entered into a definitive business combination agreement with clinical-stage biopharmaceutical company ArcheNova Biotech Corp. The transaction values ArcheNova at an implied enterprise value of $2.0 billion. Upon closing, the combined entity, ArcheNova Technology Co., Ltd, is expected to list on the Nasdaq Stock Market.

Value
$2B
Counterparty
ArcheNova Biotech Corp.
8:30 AM ET 8-K
Nasdaq/NYSE Compliance Notice Eightco Holdings Inc. ORBS

Eightco Holdings Nasdaq/NYSE Compliance Notice

Eightco Holdings Inc. has regained compliance with Nasdaq's minimum bid price requirement after its common stock closed at or above $1.00 per share for 10 consecutive business days. The company had previously received a deficiency notice on August 5, 2026, and Nasdaq has now officially closed the matter.

Counterparty
The Nasdaq Stock Market LLC
8:30 AM ET 8-K
Nasdaq/NYSE Compliance Notice Newton Golf Company, Inc. NWTG

Newton Golf Company Nasdaq/NYSE Compliance Notice

Newton Golf Company received a Staff Determination letter from Nasdaq on October 6, 2026, notifying the company that it failed to regain compliance with the $2.5 million minimum stockholders’ equity requirement. As a result, the company's common stock faces suspension and delisting unless it successfully appeals the decision. The company intends to request a hearing before a Nasdaq Hearings Panel to stay the suspension and seek continued listing.

Counterparty
The Nasdaq Stock Market LLC
8:25 AM ET 8-K
Clinical Trial Data iBio, Inc. IBIO

iBio Clinical Trial Data

iBio released preclinical body-composition data from an eight-week obese non-human primate (NHP) study of its Activin E antibody candidate, IBIO-610. The study demonstrated that combining IBIO-610 with semaglutide resulted in 93% of weight loss coming from fat compared to 77% for semaglutide alone, suggesting significant muscle preservation potential. The company plans to initiate first-in-human clinical trials in the first half of 2027.

8:21 AM ET 8-K
M&A Deal Skydance Corp SKYD

Skydance M&A Deal with Warner Bros. Discovery, Inc.

Skydance Corporation (formerly Paramount Skydance Corporation) completed its acquisition of Warner Bros. Discovery, Inc. (WBD) on October 6, 2026. In connection with the closing, the company is executing exchange and tender offers for WBD's outstanding senior notes and distributed warrants to its Class B stockholders as a dividend.

Counterparty
Warner Bros. Discovery, Inc.
8:09 AM ET 8-K
Clinical Trial Data Mirum Pharmaceuticals, Inc. MIRM

Mirum Pharmaceuticals Clinical Trial Data

Mirum Pharmaceuticals announced positive topline results from its Phase 3 EXPAND study of LIVMARLI (maralixibat) for ultra-rare cholestatic liver diseases, including biliary atresia. The study met its primary endpoint for pruritus improvement and all five secondary endpoints with statistical significance. The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in the first half of 2027 based on these results.

8:01 AM ET 8-K
M&A Deal GigCapital8 Corp. GIW

GigCapital8 M&A Deal with Quantisimo Corp.

GigCapital8 Corp. has entered into a definitive merger agreement to acquire Quantisimo Corp. through a multi-step merger process involving a new holding company, Quantisimo Holdings Corp. (PubCo). As part of the transaction, WISeQey and SealSQ will contribute their equity interests in several operating subsidiaries, including Miraex SA and SEALCOIN AG, to Quantisimo prior to the closing.

Counterparty
Quantisimo Corp.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.